Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 1, 2008The Journal of ImmunologyOpen Access

Tumor Immunotherapy by Epicutaneous Immunization Requires Langerhans Cells

View Full Paper
Ask AI
Bookmark
Share

Authors

PSPatrizia StoitznerInnsbruck Medical UniversityLGLaura K. GreenNHS Blood and TransplantJJJae Yoon JungSungkyunkwan University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Stoitzner et al. (2008) studied this question.

synapsesocial.com/papers/6a7fe1f055d60ce98e659276https://doi.org/10.4049/jimmunol.180.3.1991
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1T Cell-Mediated, IFN-γ-Facilitated Rejection of Murine B16 Melanomas1998 · 123 citations
  2. 2Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor2005 · 965 citations
  3. 3NKT Cells Enhance CD4+ and CD8+ T Cell Responses to Soluble Antigen In Vivo through Direct Interaction with Dendritic Cells2003 · 491 citations
  4. 4Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro.1985 · 1,128 citations
  5. 5Induction of Therapeutically Relevant Cytotoxic T Lymphocytes in Humans by Percutaneous Peptide Immunization2006 · 55 citations